The vaginitis treatment drug market is expected to reach US$4.52 billion by the end of 2030


Vaginitis Drug Market

NEWARK, NEWARK, UNITED STATES, April 29, 2022 / — The global vaginitis treatment drugs market is forecast to reach US$3.01 billion in 2022-2030). These insights come from a recent market research study by Future Market Insights (FMI), an ESOMAR-certified research and consulting firm.

Vaginal infections affect 40% of women worldwide. In addition, most infected people are asymptomatic. Therefore, it becomes extremely difficult to keep track of vaginitis and the treatment to be administered.

For more insights into the market, request a sample of this report at

The only way out in this regard is to create awareness of the factors that lead to vaginitis. so that none occur even with larger symptoms; Women could at least seek medical advice on this.

Several government-funded and/or private organizations emphasize educating people about vaginitis and the appropriate course of treatment. Oral medications are widely used in the current scenario.

For example – DARE-BV1, a new thermoset hydrogel containing 2% clindamycin phosphate, received QIDP (Qualified Infectious Disease Product) designation from the US FDA in August 2019. The product originated from Dare Bioscience, Inc. It is expected that such developments will encourage other players to develop new products; This will strengthen the market for drugs to treat vaginitis.

Key Findings from the Vaginitis Drugs Treatment Market Study

The nitroimidazole compound is the largest segment by drug type, accounting for 44% of the revenue share in the vaginitis treatment drugs market in 2019.

According to the drug plan, prescription (Rx) drugs contribute 3/4 of the market value share. Over-the-counter (OTC) drugs are expected to grow at a higher growth rate during the forecast period

North America and East Asia combined contributed more than half of the vaginitis treatment drug market share in 2019, with North America holding a notable market share.

Ask our analyst for more information on the report at

Partnerships and collaborations pave the way for the vaginitis treatment drug market

Partnerships strengthen the drug portfolio, broaden the consumer base and give impetus to research and development. For example — in March 2018, Bayer thrush treatment drug Canesten partnered with sketch comedy group SketchShe and media agency PHD for a campaign aimed at reducing the stigma and embarrassment surrounding the disease.

This campaign gave consumers a fair idea of ​​the BQ (Behaviour Quotient) of both companies; and also left a lasting impression on the minds of consumers.

Want more insights?

Future Market Insights brings the comprehensive research report on the forecasted sales growth at global, regional and country level and provides the analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global Vaginitis Treatment Drugs Market is segmented into details to discern each aspect of the market and present the reader with a complete market intelligence approach. The study provides compelling insights into the vaginitis treatment drugs market on the basis of drug type (nitroimidazole compound, lincosamide antibiotics, triazoles, imidazoles), indication (bacterial vaginitis, fungal vaginitis (yeast infection), trichomoniasis), route of administration (oral, cutaneous, vaginal), drug schedule (prescription drug (Rx), over-the-counter drug (OTC)) distribution channels (hospital pharmacies, retail pharmacies, drugstores, mail-order pharmacies) in seven major regions.

Order a full research report:

About Future Market Insights (FMI)

Future Market Insights (ESOMAR-certified market research firm and member of the Greater New York Chamber of Commerce) provides in-depth insights into the determinants driving demand in the market. It reveals opportunities that will fuel market growth across various segments based on source, application, distribution channel and end-use over the next 10 years.


Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For sales inquiries: [email protected]

Ankush Nikam
+91 9096684197
email us here
Visit us on social media:


Comments are closed.